Plain-English translation of NCT05922930 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new approach called TROP2 CAR engineered NK cells (KSR) — immune cells that are taken from donated cord blood, modified in the laboratory to better recognize and attack cancer cells, and then infused directly into your abdomen. The goal is to see whether this treatment is safe and whether it can help control cancers that have become resistant to platinum-based chemotherapy.
Ovarian cancer, pancreatic cancer, and related tumors often stop responding to standard chemotherapy drugs, leaving patients with limited treatment options. This trial exists to test whether engineered immune cells — which work differently than traditional chemotherapy — might offer a new way to fight these hard-to-treat cancers.
You will first receive two short courses of lymphodepleting chemotherapy ( and given through an IV over 3 hours for 3 days). A small port will be surgically placed in your abdomen to allow the engineered immune cells to be delivered directly into your peritoneal cavity. You will then receive one infusion of the modified immune cells and return to the clinic up to 16 times over several months for blood draws, biopsies, imaging scans (CT), and questionnaires to assess your symptoms and quality of life. The study team will closely monitor your safety and how well the cells work.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
United States